Ceftolozane-Tazobactam

PreclinicalSmall molecule

Ceftolozane-Tazobactam is one of 5 small molecule programs targeting Pseudomonas infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pseudomonas InfectionActive, not recruiting

Pseudomonas InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Pseudomonas Infection

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

—2

Tobrex

VViatris Specialty LLC

Coly-Mycin M

Monurol

Ceftolozane-Tazobactam

TTemple University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Febrile Neutropenia

NCT06342115

Q4 2028

Post-ApprovalRecruiting

Gram-Negative Bacterial Infections

NCT07004049

Clinical

Trials by Indication[1]

Bloodstream Infection1 trial

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

Withdrawn·TThe University of Queensland·Phase 3·NCT04238390

Gram-Negative Bacterial Infections1 trial

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting·NNational University of Singapore·Phase 4·NCT07004049·600 enrolled

Pseudomonas infection1 trial

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

Unknown status·TTemple University··NCT03510351·200 enrolled

Febrile Neutropenia1 trial

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.

Recruiting·BBeneficência Portuguesa de São Paulo·Approved·NCT06342115·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ceftolozane-Tazobactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftolozane-Tazobactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftolozane-Tazobactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Temple University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTemple University

Ceftolozane-Tazobactam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Bloodstream Infection1 trial

Gram-Negative Bacterial Infections1 trial

Pseudomonas infection1 trial

Febrile Neutropenia1 trial

References

Drug Info

Quick Facts

Related News